Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin A Cheever

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|August 21, 2003
Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanismShuwen Xu, Gary K Koski, Mark Faries, et al.
Patterns (New York, N.Y.)|December 24, 2021
New interpretable machine-learning method for single-cell data reveals correlates of clinical response to cancer immunotherapyEvan Greene, Greg Finak, Leonard A D'Amico, et al.
Journal for Immunotherapy of Cancer|November 29, 2018
Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapyNatalie J Miller, Candice D Church, Steven P Fling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2002
Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancerJames L Murray, Michael E Gillogly, Donna Przepiorka, et al.
Blood Advances|February 9, 2021
Pembrolizumab in mycosis fungoides with PD-L1 structural variantsSara Beygi, Sebastian Fernandez-Pol, George Duran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2009
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational researchMartin A Cheever, James P Allison, Andrea S Ferris, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 4, 2006
Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancerJohn Nemunaitis, Thomas Meyers, Neil Senzer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2024
A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial CancerRandy F Sweis, Gurkamal S Chatta, Rohit K Jain, et al.
Oncogene|October 9, 2002
Characterization of KLK4 expression and detection of KLK4-specific antibody in prostate cancer patient seraCraig H Day, Gary R Fanger, Marc W Retter, et al.
Science Translational Medicine|January 18, 2019
Tuberculosis following PD-1 blockade for cancer immunotherapyDaniel L Barber, Shunsuke Sakai, Ragini R Kudchadkar, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Journal of Immunology (Baltimore, Md. : 1950)|August 21, 2003
Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanismShuwen Xu, Gary K Koski, Mark Faries, et al.
Patterns (New York, N.Y.)|December 24, 2021
New interpretable machine-learning method for single-cell data reveals correlates of clinical response to cancer immunotherapyEvan Greene, Greg Finak, Leonard A D'Amico, et al.
Journal for Immunotherapy of Cancer|November 29, 2018
Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapyNatalie J Miller, Candice D Church, Steven P Fling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2002
Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancerJames L Murray, Michael E Gillogly, Donna Przepiorka, et al.
Blood Advances|February 9, 2021
Pembrolizumab in mycosis fungoides with PD-L1 structural variantsSara Beygi, Sebastian Fernandez-Pol, George Duran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2009
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational researchMartin A Cheever, James P Allison, Andrea S Ferris, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 4, 2006
Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancerJohn Nemunaitis, Thomas Meyers, Neil Senzer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2024
A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial CancerRandy F Sweis, Gurkamal S Chatta, Rohit K Jain, et al.
Oncogene|October 9, 2002
Characterization of KLK4 expression and detection of KLK4-specific antibody in prostate cancer patient seraCraig H Day, Gary R Fanger, Marc W Retter, et al.
Science Translational Medicine|January 18, 2019
Tuberculosis following PD-1 blockade for cancer immunotherapyDaniel L Barber, Shunsuke Sakai, Ragini R Kudchadkar, et al.
Pageof 4